The prognostic factors of effective ketoconazole treatment for metastatic castration-resistant prostate cancer: who can benefit from ketoconazole therapy?

We investigated the prognostic value of some variables of effective ketoconazole treatment for metastatic castration-resistant prostate cancer (mCRPC). In total, 163 patients with mCRPC were eligible, receiving ketoconazole 200–400 mg three times daily with replacement doses of prednisone. Progressi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lin, Guo-Wen, Yao, Xu-Dong, Ye, Ding-Wei, Zhu, Yao, Zhang, Shi-Lin, Dai, Bo, Zhang, Hai-Liang, Shen, Yi-Jun, Ma, Chun-Guang
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2012
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3734980/
https://ncbi.nlm.nih.gov/pubmed/22902911
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/aja.2012.57
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados